Literature DB >> 16802340

Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis.

S Van Doornum1, C Brand, B King, V Sundararajan.   

Abstract

OBJECTIVE: Among patients with rheumatoid arthritis (RA), cardiovascular mortality is increased compared with the rate among unaffected peers. In this study, 30-day mortality rates following a first acute cardiovascular event (myocardial infarction or stroke) were compared between RA patients and the general population.
METHODS: All cases of a first acute cardiovascular event between July 1, 2001 and November 30, 2003 in Victoria, Australia were identified from hospital discharge data. Individuals were classified as having RA when an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification code for RA was recorded at the index admission or during the previous 5 years. Thirty-day mortality rates were determined from linkage to the state death registry.
RESULTS: A total of 29,924 patients experienced a first cardiovascular event during the study period, 359 (1.2%) of whom had RA. Thirty-day cardiovascular mortality was 17.6% in RA patients versus 10.8% in non-RA patients. In fully adjusted models, the odds ratio (OR) for cardiovascular death in RA patients following a first acute cardiovascular event was 1.6 (95% confidence interval [95% CI] 1.2-2.2). Analysis of index event subgroups revealed that this increased case fatality rate in patients with RA was accounted for almost entirely by excess deaths following myocardial infarction. The adjusted ORs for cardiovascular death in RA after myocardial infarction and stroke were 1.9 (95% CI 1.3-2.7) and 1.2 (95% CI 0.7-2.0), respectively.
CONCLUSION: RA patients have a substantially increased risk of 30-day case fatality following myocardial infarction, but not stroke, compared with non-RA patients. This higher case fatality rate is likely to contribute to the observed overall excess of cardiovascular deaths in RA populations.

Entities:  

Mesh:

Year:  2006        PMID: 16802340     DOI: 10.1002/art.21932

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

Review 2.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 3.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

Review 4.  The vasculature in rheumatoid arthritis: cause or consequence?

Authors:  Ewa M Paleolog
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 5.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

6.  Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis.

Authors:  Sara S McCoy; Cynthia S Crowson; Hilal Maradit-Kremers; Terry M Therneau; Veronique L Roger; Eric L Matteson; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

7.  Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis.

Authors:  Paul A MacMullan; Anne M Madigan; Nevin Paul; Aaron J Peace; Ahmed Alagha; Kevin B Nolan; Geraldine M McCarthy; Dermot Kenny
Journal:  Clin Rheumatol       Date:  2014-09-26       Impact factor: 2.980

Review 8.  Managing cardiovascular risk in patients with chronic inflammatory diseases.

Authors:  Boulos Haraoui; Peter P Liu; Kim A Papp
Journal:  Clin Rheumatol       Date:  2012-01-14       Impact factor: 2.980

9.  Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

Authors:  Zurab Nadareishvili; Kaleb Michaud; John M Hallenbeck; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-08-15

10.  Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population.

Authors:  Sharon Van Doornum; Caroline Brand; Vijaya Sundararajan; Andrew E Ajani; Ian P Wicks
Journal:  Arthritis Res Ther       Date:  2010-10-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.